[The new calcium antagonist Ro 11-1781 in the treatment of ventricular tachycardia due to atrial fibrillation].
In 9 patients with tachyarrhythmia and atrial fibrillation the effect of the i.v. application of the calcium antagonist Ro 11-1781 on the av-conduction was investigated. All patients received 1 mg/kg during 2-3 minutes. A significant decrease of the ventricular rate at the end of the injection period was noted. The maximal decrease of the av-conduction of 10-32 % of the initial ventricular rate was observed 5-10 min after the injection. During 60 min the initial heart rate before application of the drug was not yet reached again. The registrations prove the inihibiting effect of Ro 11-1781 on av-conduction in atrial fibrillation, which was sufficient for therapeutic use in our cases concerning the reduction of heart rate and duration of the effect. No serious side effects were observed.
D000328:Adult; D000368:Aged; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy*; D001283:Atrioventricular Node / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D002118:Calcium / Q000037:antagonists & inhibitors*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006571:Heterocyclic Compounds / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010647:Phenyl Ethers / Q000627:therapeutic use; D013610:Tachycardia / Q000188:drug therapy*
D006571:Heterocyclic Compounds; D010647:Phenyl Ethers; D002118:Calcium
Behandlung der absoluten Tachyarrhythmie bei Vorhofflimmern mit dem neuen Kalziumantagonisten Ro 11-1781.